Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Working Capital Changes (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Other Working Capital Changes for 12 consecutive years, with $62.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Working Capital Changes rose 24.1% year-over-year to $62.1 million, compared with a TTM value of -$116.1 million through Sep 2025, down 344.72%, and an annual FY2024 reading of -$118.3 million, down 32.85% over the prior year.
  • Other Working Capital Changes was $62.1 million for Q3 2025 at CytomX Therapeutics, up from -$63.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $62.1 million in Q3 2025 and bottomed at -$116.5 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$11.0 million, with a median of -$8.0 million recorded in 2022.
  • Peak annual rise in Other Working Capital Changes hit 227.1% in 2023, while the deepest fall reached 560.38% in 2023.
  • Year by year, Other Working Capital Changes stood at $22.3 million in 2021, then increased by 27.27% to $28.4 million in 2022, then tumbled by 185.64% to -$24.3 million in 2023, then plummeted by 378.53% to -$116.5 million in 2024, then skyrocketed by 153.35% to $62.1 million in 2025.
  • Business Quant data shows Other Working Capital Changes for CTMX at $62.1 million in Q3 2025, -$63.0 million in Q2 2025, and $1.2 million in Q1 2025.